This molecularly targeted strategy takes advantage of a common differences between normal and cancer cells in their capacity to trigger p53-dependent cell death following DNA-damaging therapies since cancer cells frequently carry inactivating p53-mutations [21]. The gene discussed is TP53; the disease is cancer.